Speaker Profile
PMWC PIONEER AWARD
Groundbreaking work in viral vector-based gene therapies, significantly impacting the treatment of rare genetic diseases
M.D., Ph.D., President and CEO, Gemma Biotherapeutics
Biography
James M. Wilson, MD, PhD, is the President and CEO of Gemma Biotherapeutics (GEMMABio) and Chair of Franklin Biolabs. Previously, he served as a Professor in the Perelman School of Medicine at the University of Pennsylvania where he has led an effort to develop the field of gene therapy. His research career spanning over 40 years has focused on rare diseases and ways to treat them by gene therapy. Dr. Wilson has published 600 papers and is named on more than 1200 patents worldwide. The Wilson lab identified a new type of vector based on novel isolates of adeno-associated viruses which have become best in class for gene therapy. More recently Dr. Wilson's laboratory has focused on improved vectors for gene therapy and clinical applications of genome editing and mRNA therapy.
